Our full-service approach to Phase II & III clinical trials cuts complexity, protects timelines, guarantees inspection readiness, and ensures patient-centric execution, so you can confidently move at the speed of science.
Our integrated services have scale-ready operations, continuous risk and quality oversight, and proactive mitigation to help you:
We enable delivery excellence through proactive planning, coordination, and strategic problem-solving that drives successful enrollment and study execution. Our continuous monitoring also enables agile adjustments to recruitment strategies to reach timely study completion.
.
Our proactive and tailored approach identifies challenges, collects feedback, and creates customized strategies that maintain speed, quality, and control under expanding operational demands.
We manage operational complexity with adaptive strategies that protect timelines and participant engagement while maintaining inspection readiness. Through integrated leadership, we deliver compliant execution and audit-ready data across your study lifecycle.
Our global infrastructure and patient-centric approach address sparse populations, complex logistics, and evolving regulations. Our decentralized and hybrid models also help improve access, adherence, and execution to meet patients’ needs.
Chief Development Operations Officer - Early-Stage Biotech Company
Our clinical development and medical expertise remove barriers, making your Phase II & III trials easier every step of the way.
Partner with us to:
Advance your study globally with our operational footprint, which includes our strong presence in China
The biggest risks include rapid expansion across sites and countries, increased protocol complexity, variability in site performance, supply chain strain, and data quality challenges. Without strong governance and planning, these can lead to delays, inconsistent execution, and reduced study quality.
We manage this through integrated start-up planning, country-specific activation sequencing, and real-time enrollment tracking. By aligning regulatory, contracting, and site readiness activities, we reduce activation delays and maintain consistent enrollment momentum across regions.
We provide full-service Phase III support, including clinical operations, pharmacovigilance, biostatistics, data management, medical monitoring, and regulatory support, ensuring end-to-end execution with integrated oversight and coordinated decision-making.
We use structured governance, clear communication cadences, defined decision pathways, and transparent reporting. This helps sponsors, vendors, and sites remain aligned on priorities, timelines, and enables risk mitigation actions throughout the study.
Inspection readiness is maintained through continuous quality oversight, real-time risk monitoring, standardized processes, and ongoing documentation review, ensuring audit-ready data and compliance are built into daily operations rather than addressed at study close.
RBQM (Risk-Based Quality Management) is a proactive approach to identifying, assessing, and mitigating risks throughout a study. From RFP to DBL, it includes risk assessment, critical data/critical process identification, centralized monitoring, ongoing review, and continuous mitigation tracking.
We accelerate enrollment by optimizing site selection, engaging experienced investigators, refining pre-screening strategies, and leveraging targeted recruitment approaches. Continuous monitoring allows rapid adjustments to improve screening efficiency and retention.
We map patient pathways, engage advocacy groups, and assess real-world treatment journeys to understand where patients are found and how they access care. This enables feasibility strategies that reduce burden and improve recruitment potential.
Decentralized elements include telemedicine visits, home nursing, local labs, direct-to-patient drug supply, and wearable technologies. These help reduce travel burden, improve access, and increase retention in geographically dispersed populations.
Yes, we can transition late-stage programs through rapid study assessment, risk identification, governance stabilization, and operational takeover. This includes restoring enrollment, aligning vendors, reinforcing data quality, and implementing recovery plans to stabilize and complete the study.